Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Recent Advances in Skin Cancers
share announcement

Recent Advances in Skin Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 10555

Special Issue Editor

Dr. Syril Keena T. Que

E-Mail Website
Guest Editor
Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA
Interests: Mohs surgery; cutaneous squamous cell carcinoma; melanoma; facial reconstruction; wound healing; public health epidemiology

Special Issue Information

Dear Colleagues,

While most cutaneous squamous cell carcinomas (cSCCs) are low-risk tumors and treated definitively with surgery, a subset of cSCC is associated with metastasis and death. In recent years, the introduction of the Brigham and Women’s Hospital tumor staging system and the updated American Joint Committee on Cancer guidelines have been instrumental in predicting the risk of poor outcomes from cSCC. Gene expression profile testing of cSCC can provide additional prognostic information to guide the implementation of surveillance strategies and adjuvant therapies. The use of immunotherapy, specifically the PD1 inhibitor cemiplimab, has been a game changer in the treatment of locally advanced or metastatic cSCC.

In this Special Issue, we will highlight major advances in the staging, prognostication, and treatment of cSCC.

Dr. Syril Keena T. Que
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cutaneous squamous cell carcinoma
  • staging
  • surgical treatment
  • immunotherapy
  • cemiplimab
  • adjuvant radiation
  • gene expression profile
  • Brigham and Women’s Hospital tumor staging system
  • American Joint Committee on Cancer staging system

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 4485 KiB  
Article
AI-Driven Enhancement of Skin Cancer Diagnosis: A Two-Stage Voting Ensemble Approach Using Dermoscopic Data
by Tsu-Man Chiu, Yun-Chang Li, I-Chun Chi and Ming-Hseng Tseng
Cancers 2025, 17(1), 137; https://doi.org/10.3390/cancers17010137 - 3 Jan 2025
Cited by 1 | Viewed by 1441
Abstract
Background: Skin cancer is the most common cancer worldwide, with melanoma being the deadliest type, though it accounts for less than 5% of cases. Traditional skin cancer detection methods are effective but are often costly and time-consuming. Recent advances in artificial intelligence have [...] Read more.
Background: Skin cancer is the most common cancer worldwide, with melanoma being the deadliest type, though it accounts for less than 5% of cases. Traditional skin cancer detection methods are effective but are often costly and time-consuming. Recent advances in artificial intelligence have improved skin cancer diagnosis by helping dermatologists identify suspicious lesions. Methods: The study used datasets from two ethnic groups, sourced from the ISIC platform and CSMU Hospital, to develop an AI diagnostic model. Eight pre-trained models, including convolutional neural networks and vision transformers, were fine-tuned. The three best-performing models were combined into an ensemble model, which underwent multiple random experiments to ensure stability. To improve diagnostic accuracy and reduce false negatives, a two-stage classification strategy was employed: a three-class model for initial classification, followed by a binary model for secondary prediction of benign cases. Results: In the ISIC dataset, the false negative rate for malignant lesions was significantly reduced, and the number of malignant cases misclassified as benign dropped from 124 to 45. In the CSMUH dataset, false negatives for malignant cases were completely eliminated, reducing the number of misclassified malignant cases to zero, resulting in a notable improvement in diagnostic precision and a reduction in the false negative rate. Conclusions: Through the proposed method, the study demonstrated clear success in both datasets. First, a three-class AI model can assist doctors in distinguishing between melanoma patients who require urgent treatment, non-melanoma skin cancer patients who can be treated later, and benign cases that do not require intervention. Subsequently, a two-stage classification strategy effectively reduces false negatives in malignant lesions. These findings highlight the potential of AI technology in skin cancer diagnosis, particularly in resource-limited medical settings, where it could become a valuable clinical tool to improve diagnostic accuracy, reduce skin cancer mortality, and reduce healthcare costs. Full article
(This article belongs to the Special Issue Recent Advances in Skin Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 358 KiB  
Review
Cutaneous Squamous Cell Carcinoma: An Updated Review
by Rina Jiang, Mike Fritz and Syril Keena T. Que
Cancers 2024, 16(10), 1800; https://doi.org/10.3390/cancers16101800 - 8 May 2024
Cited by 8 | Viewed by 8459
Abstract
Representing the second most common skin cancer, the incidence and disease burden of cutaneous squamous cell carcinoma (cSCC) continues to increase. Surgical excision of the primary site effectively cures the majority of cSCC cases. However, an aggressive subset of cSCC persists with clinicopathological [...] Read more.
Representing the second most common skin cancer, the incidence and disease burden of cutaneous squamous cell carcinoma (cSCC) continues to increase. Surgical excision of the primary site effectively cures the majority of cSCC cases. However, an aggressive subset of cSCC persists with clinicopathological features that are indicative of higher recurrence, metastasis, and mortality risks. Acceleration of these features is driven by a combination of genetic and environmental factors. The past several years have seen remarkable progress in shaping the treatment landscape for advanced cSCC. Risk stratification and clinical management is a top priority. This review provides an overview of the current perspectives on cSCC with a focus on staging, treatment, and maintenance strategies, along with future research directions. Full article
(This article belongs to the Special Issue Recent Advances in Skin Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop